• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/14/25 4:11:54 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    8-K
    false000186312700018631272025-08-142025-08-14

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 14, 2025

     

     

    Tyra Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40800

    83-1476348

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2656 State Street

     

    Carlsbad, California

     

    92008

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (619) 728-4760

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    TYRA

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 14, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    99.1

    Press Release Issued on August 14, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)


     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    TYRA BIOSCIENCES, INC.

     

     

     

     

    Date:

    August 14, 2025

    By:

    /s/ Alan Fuhrman

     

     

     

    Alan Fuhrman
    Chief Financial Officer

     


    Get the next $TYRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    12/15/2023$25.00 → $15.00Buy → Neutral
    BofA Securities
    6/30/2023$27.00Outperform
    Wedbush
    2/3/2023$17.00Outperform
    Oppenheimer
    6/23/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $TYRA
    SEC Filings

    View All

    SEC Form 8-K filed by Tyra Biosciences Inc.

    8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

    8/21/25 9:43:39 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tyra Biosciences Inc.

    10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)

    8/14/25 4:17:47 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

    8/14/25 4:11:54 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

    -Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism.  Dabogratinib is a potential first-in-class, once-daily o

    8/21/25 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Announces Participation at Upcoming Investor Events

    CARLSBAD, Calif., Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events:           Virtual H.C. Wainwright "HCW@Home" series          Format: Fireside chat          Presentation Date/Time: Thursday, August 21, 2025, at 11 AM ET           H.C. Wainwright 27th Annual Global Investment Conference          Format: Fireside chat and one-on-one investor meetings          Presentation Date/Time: Wednesday,

    8/20/25 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

    - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 - CARLSBAD, Calif., Aug. 14, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress. "We see significant opportunity to transform the treatment of bladder cancer and skeletal dyspla

    8/14/25 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $1,664,700 worth of shares (163,287 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/16/25 8:06:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $1,904,002 worth of shares (186,850 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/11/25 7:44:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $11,751,304 worth of shares (1,211,198 units at $9.70) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/6/25 4:43:19 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Tyra Biosciences with a new price target

    Piper Sandler resumed coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00

    5/21/25 9:01:58 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Tyra Biosciences with a new price target

    UBS initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $28.00

    1/7/25 8:31:57 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences upgraded by BofA Securities with a new price target

    BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously

    10/18/24 7:41:59 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Fuhrman Alan

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    8/7/25 4:43:09 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Bensen Daniel

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    8/7/25 4:40:24 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Warner Douglas J

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    8/7/25 4:38:02 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    View All

    Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

    CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

    1/29/25 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

    -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

    1/10/25 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

    - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30

    11/7/24 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Financials

    Live finance-specific insights

    View All

    Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

    - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

    10/24/24 6:21:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

    CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

    10/23/24 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

    - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

    3/1/23 7:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    12/6/24 9:30:49 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/19/24 9:31:34 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

    SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/14/24 5:47:01 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care